Genesis HealthCare (GEN) Tops Q3 EPS by 12c; Guidance Reaffirmed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Genesis HealthCare Reports Third Quarter 2016 Results
November 3, 2016 4:02 PM EDTAnnounces Planned Divestiture of Facilities in Eight States to Focus on Core Markets
Recently Announced New Leases Reduce Prior Lease Obligation by $440 Million through January 2032 Third Quarter EBITDA Meets First Call Consensus Estimate
KENNETT SQUARE, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Genesis HealthCare (Genesis, or the Company) (NYSE: GEN), one of the largest post-acute care providers in the United States, today announced operating results for the third quarter ended September 30, 2016.Â
... MoreGenmab Announces Financial Results for the First Nine Months of 2016 and Improves 2016 Financial Guidance
November 2, 2016 12:02 PM EDTNovember 2, 2016; Copenhagen, Denmark;
Interim Report for First Nine Months Ended September 30, 2016
Highlights
Net Sales of DARZALEX® (daratumumab) by Janssen for the first nine months of 2016 were USD 372 million, resulting in royalty income of USD 45 million (DKK 298 million)... More